Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 1c

Amneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.21, $0.01 better than the analyst estimate of $0.20. Revenue for the quarter came in at $529 million versus the consensus estimate of $544.49 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2021 EPS of $0.78-$0.88, versus the consensus of $0.88. Amneal Pharmaceuticals sees FY2021 revenue of $2.1 billion, versus the consensus of $2.14 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Columbus McKinnon names John Linker as CFO, reaffirms FY2027 guidance
• Culp, Inc. (CULP) Misses Q4 EPS by 12c